Impact of COVID ‐19 Restrictions on Nationwide Antipsychotic Use: Results From the Trends in Drug Utilization During COVID ‐19 Pandemic in Turkey ( PANDUTI ‐ TR ) Study
- 29 January 2026
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (2) , e70336
Abstract
Introduction: The extraordinary circumstances due to the COVID‐19 pandemic and related restrictions altered the management of mental health disorders, including the use of antipsychotics. We aimed to examine the changes in antipsychotic utilization and expenditure in Turkey throughout pandemic‐associated restriction periods. Methods: Nationwide drug sales and projected prescribing data from 01.03.2018 to 31.12.2022 were obtained from IQVIA Turkey. We assessed average monthly consumption, expenditure, and quarterly prescribing levels across three periods: “before restrictions” (BfR, 01.03.2018–31.03.2020), “during restrictions” (DuR, 01.04.2020–31.03.2022), and “after restrictions” (AfR, 01.04.2022–31.12.2022). Consumption and prescribing levels were measured using “defined daily dose/1000 inhabitants/day” (DID) parameter. Results: Antipsychotic consumption throughout periods increased from 8.4 ± 0.6 DID in BfR to 9.9 ± 1.6 DID in DuR ( p < 0.001), and to 10.1 ± 0.9 DID in AfR ( p < 0.001 vs. BfR). Atypical antipsychotics followed the overall trend, whereas typical antipsychotics remained stable from DuR to AfR, deviating from this pattern. Antipsychotic expenditure rose from €16.7 m ± 1.1 m in BfR to €19.0 m ± 2.7 m in DuR ( p < 0.001), then shifted to €18.3 m ± 1.9 m in AfR ( p > 0.05 vs. BfR and DuR). High‐cost antipsychotic use increased after the pandemic onset ( p < 0.001) and remained elevated in AfR ( p < 0.001). Prescribing for schizophrenia declined from 2.2 ± 0.3 DID in BfR to 1.3 ± 0.2 DID in DuR ( p < 0.001), then escalated to 1.8 ± 0.3 DID in AfR ( p = 0.015 vs. DuR). Conclusions: Our study revealed an upsurge in antipsychotic utilization in Turkey with the start of the pandemic. A range of factors may have contributed, notably the impact of policies facilitating the dispensing of chronic medications without prescription or a tendency towards polypharmacy.Keywords
Funding Information
- Türkiye Sağlık Enstitüleri Başkanlığı (21298)
This publication has 25 references indexed in Scilit:
- FDA Eliminates the Clozapine REMS—What Comes Next?JAMA Psychiatry, 2025
- Pharmacotherapy of Psychotic Disorders in Türkiye: Insights From a National Prescription DatabaseBrain and Behavior, 2025
- Delirium and Coronavirus Disease 2019Critical Care Nursing Clinics of North America, 2024
- The need for health system strengthening in the wake of natural disasters: Lessons from the 2023 Türkiye–Syria earthquakePublic Health Challenges, 2023
- Trends in Delirium and New Antipsychotic and Benzodiazepine Use Among Hospitalized Older Adults Before and After the Onset of the COVID-19 PandemicJAMA Network Open, 2023
- Impact of the Covid‐19 pandemic on neuropsychiatric symptoms and antipsychotic prescribing for people with dementia in nursing home settingsInternational Journal of Geriatric Psychiatry, 2023
- Global impact of the COVID-19 pandemic on mental health services: A systematic reviewJournal of Psychiatric Research, 2022
- Deterioration of mental health despite successful control of the COVID-19 pandemic in South Korea.Psychiatry Research, 2021
- Haloperidol in palliative care: Indications and risksBiomedicine & Pharmacotherapy, 2020
- Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With SchizophreniaJAMA Psychiatry, 2019